Spinifex Pharmaceuticals appoints neuroscience expert as Chief Medical Officer

Ronald Marcus joins the Australian-US biotechnology company

Spinifex Pharmaceuticals, a pain drug development company, has appointed Dr Ronald Marcus as Chief Medical Officer. He will be responsible for driving the development of Spinifex’s leading drug candidate, EMA401, an oral treatment for chronic pain, and the company’s pre-clinical pipeline.

Marcus has more than 20 years’ pharmaceutical clinical development experience.

He joins biotechnology company Spinifex, which is located in Stamford, Connecticut, UN and Melbourne, Australia, after a successful career at Bristol-Myers Squibb (BMS), having held a number of senior leadership positions within BMS’s Neuroscience division.

Marcus has extensive experience in early and late drug development process and possesses both breadth and depth in all of the key functional areas of exploratory and late development, disease biology and regulatory affairs.

You may also like